Abstract
Ursodeoxycholic acid (ursodiol) has been shown to be an effective oral agent for dissolution of gallstones that also has a favorable safety profile. In the selection of patients as candidates for this treatment, stone characteristics and the functional status of the gallbladder are the two most important criteria. Small, primarily cholesterol stones (radiolucent on plain film) are the most suitable for oral dissolution therapy. In addition, a functioning gallbladder (as evidenced by visualization on oral cholecystogram) is required to concentrate the ursodiol-enriched bile and effect stone dissolution. Ursodiol should not be used during pregnancy, in women likely to become pregnant, or in severe acute or chronic intrahepatic cholestasis. Acute cholestasis and common bile duct obstruction also preclude this treatment. Screening tests include basic laboratory tests of liver function, sonographic evaluation of the gallbladder and biliary tree, plain film of the abdomen, and oral cholecystogram. Since few patients meet all the selection criteria ideally, the decision to undertake treatment with ursodiol must be based on the entire clinical profile and on the patient's willingness to accept the predicted likelihood of success.
Similar content being viewed by others
References
Tint GS, Salen G, Colalillo A, Graber D, Verga D, Speck J, Shefer S: Ursodeoxycholic acid: A safe and effective agent for dissolving gallstones. Ann Intern Med 97:351–356, 1982
Fromm H, Roat JW, Gonzalez V, Sarva RP, Farivar S: Comparative efficacy and side effects of ursodeoxycholic and chenodeoxycholic acids in dissolving gallstones. A double-blind controlled study. Gastroenterology 85:1257–1264, 1983
Fromm H: Gallstone dissolution therapy. Current status and future prospects. Gastroenterology 91:1560–1567, 1986
Fromm H, Malavolti M: Dissolving gallstones.In Advances in Internal Medicine. Stollerman GH, LaMont JT (eds). Chicago, Year Book Medical Publishers, 1988, pp 409–430
Sackmann M, Delius M, Sauerbruch T, Holl J, Weber W, Ippisch E, Hagelauer U, Wess O, Hepp W, Brendel W, Paumgartner G: Shock-wave lithotripsy of gallbladder stones. The first 175 patients. N Engl J Med 318:393–397, 1988
Leuschner U, Leuschner M, Sieratzki J, Kurtz W, Hubner K: Gallstone dissolution with ursodeoxycholic acid in patients with chronic active hepatitis and two years follow-up. A pilot study. Dig Dis Sci 30:642–649, 1985
Poupon R, Chretien Y, Poupon RE, Ballet F, Calmus Y, Darnis F: Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis. Lancet 1:834–836, 1987
Sarva RP, Farivar S, Fromm H, Poller W: Study of the sensitivity and specificity of computerized tomography in the detection of calcified gallstones which appear radiolucent by conventional roentgenography. Gastrointest Radiol 6:165–167, 1981
Schoenfield LJ, Lachin JM, The Steering Committee and The National Cooperative Gallstone Study Group: Chenodiol (chenodeoxycholic acid) for dissolution of gallstones: The National Cooperative Gallstone Study. Ann Intern Med 95:257–282, 1981
Barbara L, Sama C, Morselli Labate AM, Taroni F, Rusticali AG, Festi D, Sapio C, Roda E, Banterle C, Puci A, Formentini F, Colasanti S, Nardin F: A population study on the prevalence of gallstone disease: The Sirmione study. Hepatology 7:913–917, 1987
Trotman BW, Patella EJ, Soloway RD, Sanchez HM, Morris TA, Miller WT: Evaluation of radiographic lucency or pigment stones. Gastroenterology 68:1563–1566, 1975
Kitani K: Ursodeoxycholic acid for cholestatic jaundice. Lancet 2:49, 1988 (letter)
Fromm H: Gallstone dissolution and the cholesterol-bile acid-lipoprotein axis: Propitious effects of ursodeoxycholic acid. Gastroenterology 87:229–233, 1984 (editorial)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fromm, H. Gallstone dissolution therapy with ursodiol. Digest Dis Sci 34 (Suppl 12), S36–S38 (1989). https://doi.org/10.1007/BF01536660
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01536660